Latest Commercialization News

Page 158 of 381
Xamble Group Limited reported a sharp 39% revenue decline and a doubling of losses in H1 FY2025, driven by strategic exit from Taiwan and increased technology spending. Despite financial setbacks, operational metrics show strong user and client growth, underpinning the company’s Southeast Asia-focused transformation.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.
Ada Torres
Ada Torres
29 Aug 2025
PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Sumitomo Corporation has committed to a strategic equity investment in Mitchell Services’ Loop Decarbonisation JV, valuing the business at $24 million and signaling confidence in its mining sector emissions solutions.
Maxwell Dee
Maxwell Dee
29 Aug 2025
PPK Group reported a statutory loss in FY25 driven by a significant non-cash impairment of its lithium-sulfur battery investment, while its ballistics division achieved record revenue and battery sales gained momentum from government programs.
Victor Sage
Victor Sage
29 Aug 2025
PPK Group Limited reported a significant statutory loss for FY25, driven by a major non-cash impairment on its Li-S Energy investment, while its ballistic protection arm Craig International Ballistics delivered exceptional revenue growth.
Victor Sage
Victor Sage
29 Aug 2025
Hiremii Limited reported a near-flat revenue for FY2025 with a 25% increase in net loss, while pushing forward its AI-driven recruitment platform and completing a key acquisition to expand market reach.
Sophie Babbage
Sophie Babbage
29 Aug 2025
RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.
Sophie Babbage
Sophie Babbage
29 Aug 2025
WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.
Ada Torres
Ada Torres
29 Aug 2025
Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.
Logan Eniac
Logan Eniac
29 Aug 2025
Cettire Limited reported stable revenue for FY25 despite a challenging luxury market, but profitability sharply declined due to increased promotional activity and softer demand.
Logan Eniac
Logan Eniac
29 Aug 2025